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Systemic  mastocytosis  is a myeloproliferative  neoplasm  with  varying  presentation  that  is caused  by inﬁl-
tration of  neoplastic  mast  cells  into  extracutaneous  tissues.  Cytoreductive  therapy  is  used  to control  organ
dysfunction  in aggressive  systemic  mastocytosis  and  is sometimes  needed  for control  of  severe  refractory
symptoms  in  patients  with  indolent  disease.  However,  current  standard  cytoreductive  agents  are  limited
by  their  suboptimal  degree  and  duration  of response  and  associated  signiﬁcant  toxicities,  highlighting
the  need  for  novel  treatments  for systemic  mastocytosis.  Recent  studies  have  identiﬁed  CD30  as  a  thera-
peutic target  in  systemic  mastocytosis,  as  CD30  is  expressed  on  a  majority  of  neoplastic  mast  cells.  In this
case  series,  the  clinical  outcomes  of  4  patients  with  aggressive  or indolent  systemic  mastocytosis  treated
with  the  anti-CD30  antibody-drug  conjugate  brentuximab  vedotin  are  reported.  Two  patients  showedlinical trial
ematologic neoplasms
rentuximab vedotin
evidence  of  a  response  to treatment  with  a reduction  in  disease  burden,  1 of  which  has  demonstrated
a  durable  response  with  ongoing  beneﬁt  for more  than  3 years.  Treatment  with  brentuximab  vedotin
was  well-tolerated  with  side  effects  that  were effectively  managed  by  dose  modiﬁcations.  The  results
presented  suggest  that  brentuximab  vedotin  is  active  in systemic  mastocytosis  and  can  induce  durable
responses  with  a manageable  toxicity  proﬁle.. IntroductionSystemic mastocytosis (SM) is a myeloproliferative neoplasm
aused by clonally proliferating mast cells that inﬁltrate into
Abbreviations: 2-CdA, 2-chlorodeoxyadenosine; ADC, antibody-drug conju-
ate; ALCL, anaplastic large cell lymphoma; ANC, absolute neutrophil count; ASM,
ggressive systemic mastocytosis; BM,  bone marrow; CT, computed tomography;
CNM, European Competence Network on Mastocytosis; G-CSF, granulocyte colony
timulating factor; Hct, hematocrit; Hgb, hemoglobin; HL, Hodgkin’s lymphoma;
FN-,  interferon-; IWG-MRT, International Working Group-Myeloproliferative
eoplasms Research and Treatment; MMAE, monomethyl auristatin E; ORR, objec-
ive  response rate; PCR, polymerase chain reaction; PLT, platelet count; Q1W, weekly
or 3 weeks of a 4 week cycle; Q3W, every 3 weeks; Q6W, every 6 weeks; SM,
ystemic mastocytosis; TWC, total white count.
 Clinical Trial Registration Number: NCT01461538.
∗ Corresponding author. Tel.: +1 503 418 2294; fax: +1 503 494 3257.
E-mail address: borate@ohsu.edu (U. Borate).
ttp://dx.doi.org/10.1016/j.leukres.2016.02.010
145-2126/© 2016 Elsevier Ltd. All rights reserved.© 2016  Elsevier  Ltd. All  rights  reserved.
extracutaneous tissues. The bone marrow (BM) is almost always
involved, though the spleen, liver, skeletal system, lymph nodes,
and gastrointestinal tract are also commonly affected [1]. Patients
with aggressive systemic mastocytosis (ASM) exhibit organ dys-
function due to mast cell involvement and have a signiﬁcantly
reduced median survival (approximately 41 months) when com-
pared with age-matched controls and patients with indolent SM
(approximately 198 months) [2–4]. In ASM, cytoreductive therapy
is used to control symptoms and complications of mast cell inﬁl-
tration [2,3,5]. Patients with indolent SM do not show end organ
damage but are frequently affected by symptoms due to mast cell
mediator release. Approaches to management include avoidance
of symptom triggers and the use of antimediator drugs such as H1
and H2 histamine receptor antagonists, antileukotriene agents, and
cromolyn sodium. However, in some individuals with indolent SM,
severe symptoms cannot be adequately controlled by this approach
and cytoreductive therapy is required [6].
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Interferon-alpha (IFN-) and 2-chlorodeoxyadenosine (2-CdA)
re the most commonly used cytoreductive treatments for SM [5,7].
n multiple small case series, overall response rates of approxi-
ately 50% have been reported with each of these agents, though
urable remissions are uncommon [7–16]. Cytoreductive ther-
py is also associated with frequent side effects. For IFN- these
nclude constitutional symptoms, depression, and thrombocytope-
ia, while the most signiﬁcant side effects of 2-CdA treatment are
requent marrow suppression and CD4 depletion [8,17]. Although
he vast majority of SM cases are associated with the KITD816
 mutation, for the few patients without this mutation imatinib
esylate can be an effective therapy [1,18].
The recent detection of CD30 expression on a majority of neo-
lastic mast cells has identiﬁed a new potential therapeutic target
n SM [19–21]. Brentuximab vedotin (ADCETRIS®) is an anti-CD30
ntibody-drug conjugate (ADC) consisting of the chimeric IgG1
ntibody cAC10, speciﬁc to human CD30, covalently attached to the
icrotubule-disrupting agent monomethyl auristatin E (MMAE)
y a protease-cleavable linker. The anticancer activity of brentux-
mab vedotin is due to the binding of the ADC to CD30-expressing
ells, followed by internalization of the ADC-CD30 complex, and
he release of MMAE  via proteolytic cleavage within the cell. Bind-
ng of MMAE to tubulin disrupts the microtubule network within
he cell, inducing cell cycle arrest and apoptotic death of the cell
22].
Two pivotal phase 2 studies have demonstrated the efﬁcacy and
afety of brentuximab vedotin administered every 3 weeks (Q3W)
s a single agent for treating relapsed or refractory Hodgkin lym-
homa (HL) and systemic anaplastic large cell lymphoma (ALCL),
alignancies known to express high levels of CD30. The objective
esponse rate (ORR) for HL patients was 75%, with approximately
ne-third of patients achieving a complete remission [23]. ALCL
atients had an ORR of 86%, with over 50% of patients achieving a
omplete remission [24]. In both studies, brentuximab vedotin was
enerally well-tolerated with manageable side effects.
In this case series, 4 patients with CD30-positive systemic mas-
ocytosis were identiﬁed and treated with brentuximab vedotin.
wo of the 4 patients showed evidence of a response to treatment
ith a reduction of disease burden. The clinical outcomes of these
 patients are described here.
. Methods
A phase 2, open-label study with a primary objective of
valuating the antitumor activity of brentuximab vedotin in
atients with CD30-positive nonlymphomatous malignancies
NCT01461538) was sponsored by Seattle Genetics, Inc. (see
upplemental information). Patients with CD30-positive nonlym-
homatous malignancies who failed, refused, or were deemed
neligible for standard therapy were identiﬁed through a com-
anion screening protocol that employed immunohistochemical
taining of tissue biopsy samples with an anti-BerH2 antibody
r ﬂow cytometric analysis of BM samples with an anti-BerH8
ntibody. Three dosing regimens of brentuximab vedotin were
valuated in this study. Enrolled patients with all eligible patholo-
ies received a starting dose of either 1.8 mg/kg Q3W or, following
n amendment to the protocol to increase the starting dose level,
.4 mg/kg brentuximab vedotin Q3W. An additional amendment
hen allowed for enrollment of some patients with acute leukemia
r myelodysplastic syndrome to be treated with a starting dose of
.2 mg/kg brentuximab vedotin on Days 1, 8, and 15 of each 4-week
ycle (Q1W).Monitoring for unacceptable toxicities was conducted and
afety data were reviewed; dose modiﬁcations were dependent
pon the type and severity of the toxicity. If unacceptable toxicities
ere observed, patients initially treated at a dose of 2.4 mg/kg Q3Wearch 44 (2016) 25–31
could have their dose decreased to 1.8 mg/kg Q3W and patients ini-
tially treated at a dose of 1.8 mg/kg could have their dose decreased
to 1.2 mg/kg Q3W. Dose delays of up to 3 weeks were also permit-
ted for patients who  received 1.8 mg/kg or 2.4 mg/kg brentuximab
vedotin Q3W. For patients treated with 1.2 mg/kg brentuximab
vedotin on Days 1, 8, and 15 of each cycle who experienced unac-
ceptable toxicity, dosing could be delayed for up to 2 weeks and/or
could be decreased to 1.0 mg/kg Q1W.
A total of 83 patients with CD30-positive disease, including 4
patients with CD30-positive SM,  were treated during this study.
All enrolled patients were identiﬁed as CD30-positive on a com-
panion screening study. In the screening study, BM specimens
from 8 patients with mast cell disease (6 with SM,  1 with mast
cell leukemia, and 1 with chronic mast cell leukemia) were evalu-
ated by ﬂow cytometry and/or immunohistochemistry; 7 patients
were shown to have CD30-positive disease. Systemic mastocyto-
sis patients were enrolled into the brentuximab vedotin 1.8 mg/kg
and 2.4 mg/kg Q3W dosing cohorts, though one patient (case 4)
received a starting dose of 1.2 mg/kg Q3W due to renal insufﬁciency
at baseline. Brentuximab vedotin was  administered to SM patients
via intravenous infusion over a period of 30 min  on Day 1 of each
21-day cycle. Response assessments in SM patients were performed
at Cycles 2 and 4, and every 4 cycles thereafter while patients
were receiving treatment, and included a complete blood count
with differential and a BM biopsy. The overall mast cell burden and
CD30-positive mast cell burden were evaluated by immunohisto-
chemical staining of the BM biopsy samples. Adverse events were
recorded from Day 1 pre-dose through the end of study visit, or
30 days after the last study treatment, whichever was later. Patients
with clinical beneﬁt or better were eligible to continue treatment
with brentuximab vedotin until disease progression, unacceptable
toxicity, or study closure.
The screening and treatment studies were conducted at inves-
tigational sites following approval by an Investigational Review
Board in accordance with the Declaration of Helsinki. All patients
provided informed consent prior to administration of any study
treatment.
3. Results
Of the 83 patients overall that were enrolled and treated in this
study, 55 patients (66%) completed the study per protocol whereas
28 patients (34%) discontinued the study early. Reasons for study
discontinuation included death (28%), study termination by the
sponsor (4%), and patient withdrawal of consent (2%).
This study was  designed to evaluate patients with a broad range
of nonlymphomatous lesions. Therefore, the clinical data collected
were not coordinated with standard SM response criteria. As such,
chart reviews for the 4 patients with SM presented here were per-
formed by the investigators in order to collect relevant clinical data
that were not recorded in the original study database.
The ﬁrst consensus response criteria for SM were published
by Valent et al. in 2007 [25] and were based upon previously
proposed SM response criteria [26], with minor modiﬁcations, to
assess the efﬁcacy of various treatments [7,27]. During the course
of the present study, updated consensus response criteria for ASM
were published by a joint committee of experts from the Interna-
tional Working Group-Myeloproliferative Neoplasms Research and
Treatment (IWG-MRT) and the European Competence Network on
Mastocytosis (ECNM) [3,28]. The case reports presented herein give
consideration to the established response criteria at the time of
study onset and the more recently developed response criteria.
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Fig. 1. Pre- and post-treatment bone marrow biopsy results in a patient with aggressive systemic mastocytosis. (A) Pre-treatment bone marrow biopsy (40× in both panels)
from  the patient in case 1 showing extensive inﬁltration of spindle mast cells with interspersed small areas of normal hematopoietic elements (hematoxylin and eosin stains
[H&E], left panel). The majority of mast cells showed variable CD30 expression by immunohistochemistry (right panel). (B) Pre-treatment bone marrow biopsy (10× in both
panels)  from the patient in case 1 reveals mostly mast cell inﬁltrates with small pockets of normal marrow (H&E, left panel). CD117 staining of the biopsy shows strong
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.1. Case 1
A 62-year-old male with a past medical history of diabetes
ellitus, rheumatoid arthritis, and coronary artery disease devel-
ped sudden vision loss, secondary to a pseudomonas corneal
nfection. At initial diagnosis, the patient was found to have new
nset pancytopenia with an absolute neutrophil count (ANC) of
. His total white count (TWC) was 1.0 × 109/L, hemoglobin (Hgb)
09 g/L, hematocrit (Hct) 0.31, and platelet count (PLT) 192 × 109/L.
is serum tryptase level was elevated at 276 ng/mL (normal
–10 ng/mL). A BM biopsy revealed variable cellularity with sev-
ral ﬁbrotic areas containing spindle cells, which stained intensely
ositive for CD30 and tryptase. Overall, 35% of BM cells were neo-
lastic mast cells with 70% of the mast cells demonstrating CD30
xpression (Fig. 1A). Reticulin staining demonstrated 1+ BM ﬁbrosis
nd the BM was positive for the KITD816 V mutation by polymeraseels) after 8 cycles of brentuximab vedotin treatment in the patient in case 1 shows
17 staining of the same biopsy demonstrates a considerably decreased number of
anel).
chain reaction (PCR). Based on these ﬁndings, the patient was diag-
nosed with ASM. He received 2 cycles of 2-CdA 4 weeks apart with
a minimal response and was hospitalized for symptomatic anemia
requiring transfusion of packed red blood cells.
A baseline BM biopsy at study enrollment demonstrated a mast
cell burden that had increased to 50% of BM cells (Fig. 1B). His
neutropenia responded to treatment with pegylated granulocyte
colony stimulating factor (G-CSF) (Fig. 2).
After 4 doses of brentuximab vedotin at 1.8 mg/kg Q3W, the
patient developed Grade 2 peripheral neuropathy and dosing was
delayed for 5 weeks until his symptoms improved to Grade 1.
At that time he was  restarted on a reduced dose of brentuximab
vedotin (1.2 mg/kg Q3W). A BM biopsy following Cycle 8 of bren-
tuximab vedotin demonstrated a signiﬁcant reduction in the degree
of marrow inﬁltration by CD117-positive mast cells, and the return
of normal hematopoietic elements (Fig. 1B and C). The patient con-
28 U. Borate et al. / Leukemia Research 44 (2016) 25–31
Fig. 2. Response to brentuximab vedotin in a patient with aggressive systemic mastocytosis. Total white cell count, absolute neutrophil count, tryptase levels, and growth
factor  support over time in the patient in case 1 with aggressive systemic mastocytosis who was  treated with brentuximab vedotin.
Table 1
Patient Response to Treatment with Brentuximab Vedotin.
Case KITD816 V
Mutation Status
Pre-treatment IHC
Mast Cell Findings
Response
According to Valent
et al. Criteria
Response
According to
IWG-MRT/ECNM
Criteria
Cycles of Brentuximab Vedotin Received Patient Still on
Brentuximab
Vedotin Treatment
Case 1 Positive Tryptase: positive
Reticulin: 1+
CD117: positive
CD30: positive
(70%)
Major Response
with Incomplete
Remission
Partial Remission 44 Yes
Case  2 Positive Tryptase:positive
CD117: positive
CD30: positive
(30–40%)
No response Stable Disease 8 No
Case  3 Negative Tryptase:positive
CD117: positive
CD2: positive
CD25: positive
CD30: positive
(15%)
Major Regression
of systemic
mediator-related
symptoms
N/A 11 No
Case  4 Unknown Tryptase:positive
CD30: positive
(50%)
No Response No Response 3 No
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lasms  Research and Treatment; N/A = not applicable.
inued treatment with pegylated G-CSF through Cycle 23, after
hich his ANC has remained normal without growth factor support
Fig. 2). Serial BM biopsies performed every 4 cycles demonstrated
table reduction of BM mast cell involvement to 20% from Cycle
2 through Cycle 24. An increase in BM mast cell burden to 35%
as noted at Cycle 28 but on the following biopsy at Cycle 32,
t had decreased to 8%. Serum tryptase levels dropped on treat-
ent (Fig. 2), reaching a ﬁnal on-study value of 120 ng/mL at Cycle
9. Due to persistent Grade 1 neuropathy after Cycle 30, the dose
nterval of brentuximab vedotin 1.2 mg/kg was increased to every
 weeks (Q6W). Even with this change in dosing, the patient’s
NC remained stable. Based on these ﬁndings, the patient was
etermined to have a Major Response with Incomplete Remission
ccording to the criteria of Valent et al. [25] and a Partial Remission
sing the IWG-MRT/ECNM criteria (Table 1) [28].
The patient received a total of 39 cycles of brentuximab vedotin
uring the course of the study and he continued treatment withistochemistry; IWG-MRT = International Working Group-Myeloproliferative Neo-
brentuximab vedotin on a Q6W schedule after study closure. Thus
far, the patient has completed 44 cycles of brentuximab vedotin
over the course of 44 months. His most recent peripheral blood
counts were TWC  of 5.0 × 109/L, ANC 3.5 × 109/L, Hgb of 135 g/L, and
PLT of 133 × 109/L. Additionally, his tryptase level dropped further
to 109 ng/mL when last measured following study closure. With
the exception of the described peripheral neuropathy, the patient
has tolerated treatment with brentuximab vedotin well.
3.2. Case 2
A 79-year-old male with a history of hypertension, hyper-
lipidemia, coronary artery disease, and obstructive sleep apnea
syndrome was  referred for new onset pancytopenia associated with
fatigue and generalized weakness. His blood counts on presenta-
tion showed a TWC  of 2.8 × 109/L with an ANC of 1.1 × 109/L, and
his Hgb was 108 g/L, Hct was  0.31, and PLT was 225 × 109/L. A
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M biopsy revealed a hypercellular marrow with 40% inﬁltrating
nd strongly CD117- and tryptase-positive spindle shaped mast
ells. Approximately 30–40% of these mast cells stained positive for
D30. There was also signiﬁcant paratrabecular ﬁbrosis and reduc-
ion of normal trilineage hematopoiesis. His serum tryptase level
as 224 ng/mL. A computed tomography (CT) scan of his abdomen
nd pelvis demonstrated splenomegaly of 15.5 cm with diffuse,
atchy, sclerotic disease involving the pelvis, sacrum, spine, and
ibs. Based on these ﬁndings, he was diagnosed with ASM. Subse-
uent BM testing was positive for the KITD816 V mutation.
At the time of enrollment, approximately 5 months after his
nitial diagnosis, a baseline study BM biopsy showed 75% mast
ells, his leukopenia and neutropenia persisted, and his Hgb and
ct remained low. After 2 cycles of brentuximab vedotin 1.8 mg/kg
3W, his blood counts did not change signiﬁcantly from baseline
evels and a repeat BM biopsy showed modest improvement, with
he percentage of mast cells decreased to 40%. An increase in nor-
al  hematopoietic elements and stable reticulin staining were also
bserved. After 2 additional infusions of brentuximab vedotin 1.8
g/kg Q3W, the patient’s BM biopsy showed 55% of marrow cells
o be mast cells. Based on the IWG-MRT/ECNM response criteria,
he patient had Stable Disease (Table 1) [28].
After a total of 7 cycles of brentuximab vedotin, the patient
eveloped Grade 2 sensory and motor peripheral neuropathy caus-
ng delay of further treatment for 6 weeks until the neuropathy
mproved to Grade 1. He received 1 additional infusion of bren-
uximab vedotin at a reduced dose of 1.2 mg/kg. A repeat BM
iopsy after Cycle 8 demonstrated no evidence of cytoreduction
ith a BM mast cell burden of 48% and the serum tryptase level
as 252 ng/mL. No additional cycles of brentuximab vedotin were
dministered and 1 month later the patient was removed from the
tudy due to clinical progression based on investigator assessment.
.3. Case 3
A 34-year-old otherwise healthy female with a 6-year history
f a waxing and waning pruritic urticarial rash and a 20-year his-
ory of loose stools developed markedly worsening gastrointestinal
ymptoms including fecal urgency, nausea, and abdominal discom-
ort. At initial presentation, she had Grade 3 diarrhea with watery
tools 4–8 times daily that signiﬁcantly interfered with her activ-
ties of daily living. She underwent colonoscopy and the entire
olonic mucosa appeared grossly normal. Random biopsies were
btained from throughout the examined colon, revealing a dense
ast cell inﬁltrate throughout the lamina propria, staining positive
or CD117. Aberrant expression of CD2 and CD25 by mast cells was
lso noted. Her blood counts were normal: TWC  5.5 × 109/L, Hgb
19 g/L, Hct 0.36, and PLT 308 × 109/L. Her serum tryptase was  ele-
ated at 42 ng/mL. Her BM biopsy showed a normocellular marrow
ith trilineage hematopoiesis. There was a dense mast cell inﬁl-
rate (8%) with greater than 25% of the mast cells exhibiting spindle
r atypical morphology. By immunohistochemistry, the mast cell
nﬁltrate was tryptase-, CD117-, CD2-, and CD25-positive. There
as paratrabecular ﬁbrosis and osteosclerosis associated with the
ast cell inﬁltrates. The BM was tested for the KITD816 V mutation
y PCR ampliﬁcation and bi-directional sequencing and no muta-
ion was identiﬁed. Abdominal ultrasound showed no evidence of
epatosplenomegaly and a complete bone survey showed no evi-
ence of osteosclerotic lesions. Based on these ﬁndings, the patient
as diagnosed with indolent SM.  She received treatment with
omplete histamine blockade, cromolyn sodium, and leukotriene
eceptor antagonists with no improvement in her Grade 3 diarrhea
r urticarial rash.
To qualify for the study, an additional BM biopsy and aspirate
ere performed which demonstrated a baseline marrow mast cell
urden of 8% by immunohistochemistry, of which 15% stained pos-earch 44 (2016) 25–31 29
itive for CD30. By ﬂow cytometry, 37% of marrow mast cells on
an aspirate sample expressed CD30. After 3 cycles of brentuximab
vedotin 2.4 mg/kg Q3W, her diarrhea improved to Grade 1 with 1
or 2 bowel movements daily and her urticarial rash resolved com-
pletely. After 3 cycles of treatment, a repeat marrow biopsy sample
showed a total mast cell burden of 16%, an increase that was felt
by the local hematopathologist to be due to sampling bias. A sub-
sequent BM biopsy obtained after 7 cycles of treatment showed 4%
marrow mast cells. No signiﬁcant changes in her serum tryptase
levels were noted. The patient developed an intermittent Grade 1
peripheral neuropathy after Cycle 2 that increased to Grade 2 after
Cycle 7. Treatment was  withheld for 6 weeks and was  resumed at
an attenuated dose of 1.2 mg/kg Q3W after her neuropathy symp-
toms improved to Grade 1. She was considered to have a Major
Regression of systemic mediator-related symptoms according to
the criteria of Valent et al. (Table 1) [25]. The IWG-MRT/ECNM cri-
teria do not address responses in indolent SM.  She discontinued
treatment after 11 cycles of brentuximab vedotin due to plans to
conceive a child. A BM biopsy obtained after Cycle 11 showed 8%
mast cells and her serum tryptase remained stable. At the time of
this report, the patient has been off of therapy for approximately
52 weeks; her Grade 1 diarrhea symptoms remain unchanged and
her peripheral neuropathy was resolved.
3.4. Case 4
A 77-year-old male with a history of type 2 diabetes melli-
tus, coronary artery disease, hypertension, chronic kidney disease,
hyperlipidemia, degenerative joint disease, cholelithiasis, and
benign prostatic hypertrophy presented with diarrhea, anemia,
symptomatic splenomegaly and ascites as demonstrated by CT, as
well as lytic and blastic bony lesions evident upon skeletal survey. A
work-up including a BM biopsy revealed hypercellularity with 40%
of BM cells identiﬁed as malignant tryptase-positive mast cells;
50% of the BM mast cells expressed CD30. The KITD816 V muta-
tion status of the patient is unknown. At baseline, the patient’s
TWC was 8.5 × 109/L, Hgb was  97 g/L, PLT was  252 × 109/L, and ANC
was 2.0 × 109/L. Other notable ﬁndings included reduced albumin
(24 g/L) which was concerning for potential SM gut involvement.
The patient also had chronic renal insufﬁciency with a stable crea-
tinine clearance of 28 mL/min.
The patient was  treated with brentuximab vedotin at a reduced
dose of 1.2 mg/kg Q3W due to his underlying renal insufﬁciency.
After Cycle 2, a response assessment demonstrated progression of
his anemia with Hgb of 79 g/L, though his TWC, neutrophil, and PLT
all remained stable. A BM biopsy demonstrated persistent hyper-
cellularity with 30% mast cells.
The patient began to experience symptomatic deterioration
2 days after the Cycle 3 Day 1 administration of brentuximab
vedotin. At that point, his diarrhea worsened to Grade 3 and was
accompanied by Grade 3 vomiting and Grade 3 dehydration, though
all symptoms were considered unrelated to brentuximab vedotin
treatment. At the same time, the patient developed Grade 2 aspi-
ration pneumonia that progressed to Grade 4 sepsis, both of which
were considered unrelated to treatment with brentuximab vedotin.
One month after the Cycle 3 Day 1 dose of brentuximab vedotin, the
patient died of progressive disease.
4. Discussion
Recent studies of the immunological and molecular phenotype
of mast cells from patients with SM have led to improvements in the
diagnosis and classiﬁcation of this disease. Currently, cytoreduc-
tive therapy is indicated for SM patients with aggressive disease or
for individuals with indolent disease and severe mediator-release
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ymptoms that are not adequately controlled with a combination of
ntihistamines, antileukotriene agents, and cromolyn sodium [6].
owever, the treatment of SM with conventional therapies (IFN-
nd 2-CdA) is associated with signiﬁcant side effects and short-
ived responses [7–17], demonstrating the need for novel therapies
ith longer durations of response that are also well-tolerated.
CD30 is a transmembrane glycoprotein belonging to the tumor
ecrosis factor superfamily that is generally expressed only on acti-
ated or proliferating B and T cells and is absent or expressed at very
ow levels in normal tissues [29]. Activation of CD30 by its ligand,
D30L, can have pleiotropic effects which depend on the cells on
hich it is expressed [30]. Expression of CD30 has been demon-
trated in malignancies involving tissues of both lymphoid and
onlymphoid origin, including HL [31], mesenchymal tumors [32],
nd acute myelogenous leukemia [33]. Additionally, recent work
as demonstrated that CD30 is frequently expressed on neoplas-
ic mast cells [34]. In a study by Sotlar et al., CD30 expression was
etected by immunohistochemistry in marrow mast cells from 11
f 13 (85%) patients with advanced disease (including smoldering
M,  ASM, and mast cell leukemia). In contrast, CD30 expression was
etected in only 12/45 (27%) of patients with indolent disease [20].
owever, in a subsequent study by Morgado et al. that employed
ow cytometry to detect CD30, high rates of CD30 expression were
etected in marrow mast cells in both aggressive (8/8, 100%) and
ndolent (98/123, 80%) disease [19]. Together, these studies sug-
est that CD30 is a viable therapeutic target for patients with SM,
articularly ASM.
The current consensus response criteria for ASM suggest that the
M mast cell burden is best quantiﬁed using morphologic analysis
nd immunohistochemical methods on the core BM biopsy [28].
owever, multiparameter ﬂow cytometry is the preferred method
f immunophenotyping of several aberrantly expressed surface
arkers present in SM as it allows for the sensitive detection
f these markers and quantitative evaluation of antigen expres-
ion in large numbers of mast cells, even if these mast cells are
resent at low frequencies within individual samples [35]. Based
n ﬂow cytometry results from a subset of ASM and indolent
M BM samples that were also stained by immunohistochemistry,
ow cytometry appears to be a more sensitive method for detect-
ng CD30 than immunohistochemistry [19]. Multiparameter ﬂow
ytometry has also proven useful in the classiﬁcation of several
ubtypes of SM based on surface antigen expression and these dis-
inct immunophenotypes were associated with both the genetic
arkers of SM and its clinical behavior [36].
Brentuximab vedotin is an anti-CD30 ADC that delivers the
icrotubule-disrupting agent MMAE  to CD30-expressing cells and
as been shown to be a highly active agent in the treatment of CD30
xpressing lymphomas [22–24]. Though this case series is the ﬁrst
eport to explore the clinical activity of brentuximab vedotin in
he treatment of SM,  a recent publication has demonstrated that
rentuximab vedotin has anti-neoplastic activity in vitro against
D30-expressing transformed human mast cell lines and patient
erived primary neoplastic mast cells [37]. In the current case
eries, 4 patients with SM were treated with brentuximab vedotin
Table 1) at starting doses of 1.2-2.4 mg/kg Q3W. Two  patients (1
ith ASM and 1 with indolent SM)  showed evidence of a response to
reatment with a reduction of disease burden, and 1 patient with
SM is still receiving brentuximab vedotin treatment after study
losure, with ongoing clinical beneﬁt.
In the patient with ASM in case 1, the response to bren-
uximab vedotin has been durable and the treatment has been
ell-tolerated. At this point, the patient has been on treatmentor 44 months and has maintained normal peripheral blood counts
ithout growth factor support for over a year. He did experience a
eripheral neuropathy that necessitated lowering the brentuximabearch 44 (2016) 25–31
dose to 1.2 mg/kg and increasing the intervals between infusions to
6 weeks, after which his neuropathy has remained at Grade 1.
The patient in case 3 had symptomatic indolent SM that was
poorly controlled with standard therapy. On treatment with bren-
tuximab vedotin, she experienced Major Regression of her systemic
mediator-related symptoms under the consensus criteria of Valent
et al. [25]. Due to Grade 2 neuropathy, treatment was withheld and
was resumed at 1.2 mg/kg Q3W after her neuropathy symptoms
improved to Grade 1. She discontinued treatment after Cycle 11,
with plans to conceive a child. Now off therapy for approximately
52 weeks, her tryptase level remains stable, her Grade 1 diarrhea is
unchanged, and her peripheral neuropathy has resolved.
Two additional study patients with SM were treated with bren-
tuximab vedotin. One had a high burden of disease affecting his
BM and spleen and achieved a best response of Stable Disease for
6 months while undergoing treatment with brentuximab vedotin
at 1.8 mg/kg Q3W. However, this patient required a dose delay
and reduction to 1.2 mg/kg Q3W due to peripheral sensory and
motor neuropathies. Shortly after the dose reduction, the patient
was removed from the study due to progressive disease, suggest-
ing that this lower dose of brentuximab vedotin was  not enough
to control his disease. The other patient presented with advanced
disease, but did not show evidence of therapeutic beneﬁt with
clinical progression after 3 cycles of treatment with brentuximab
vedotin. This patient was  treated with a reduced starting dose of
brentuximab vedotin at 1.2 mg/kg Q3W due to underlying renal
insufﬁciency; however, it is unclear whether his lack of response
to treatment was  due to this lowered dosage. Though brentux-
imab vedotin is highly effective in treating both relapsed HL and
systemic ALCL, malignancies deﬁned by their expression of CD30,
not all patients respond to treatment and resistance can develop in
patients who  initially respond. Mechanisms of resistance to bren-
tuximab vedotin have been studied in HL and ALCL cell lines and
primary patient samples [38,39]. Studies in these cell lines sug-
gest that downregulation of CD30 expression is associated with
the development of resistance to brentuximab vedotin. However,
results in both cell lines and clinical samples show a more consis-
tent association with the development of resistance to brentuximab
vedotin and an increased expression of multidrug resistance efﬂux
pumps, which may  increase the transport of brentuximab vedotin
out of the target cells [38].
5. Conclusions
This small case series provides evidence that brentuximab
vedotin is an active and well-tolerated agent in the treatment of
SM with side effects that are effectively managed by dose modi-
ﬁcations. There are a limited number of cytoreductive agents that
are effective in this rare yet debilitating disease. These results show
brentuximab vedotin to be a promising treatment option in the
management of both aggressive and refractory symptomatic indo-
lent SM that deserves to be studied more extensively. Larger studies
are needed to better deﬁne response rates to treatment with bren-
tuximab vedotin and to explore the efﬁcacy and tolerability of
different dosing schedules. Furthermore, efforts to understand the
mechanisms of resistance to brentuximab vedotin in mast cells and
to characterize biomarkers that predict responses will be important
in deﬁning the role of brentuximab vedotin in the clinical manage-
ment of SM.
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